49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 56-57

Background

Table

Table

Breast conservation surgery (BCS) is a low-morbidity procedure, yet its complications can impact the patient’s quality of life. Due to a paucity of literature on the social factors affecting BCS outcomes, our study aimed to assess the impact of racial factors on postoperative complications.

Methods

A retrospective chart review was conducted between 2015 and 2019 on patients undergoing BCS.

Results

A total of 332 patients fit the criteria. Fifty-five (16.7%) had complications, of which 11 (3.6%) had hematoma, 27 (8.2%) had wound infection, 6 (1.8%) had wound dehiscence, and 17 (5.13%) had persistent pain. A total of 68 patients (20.6%) had seroma. Adjuvant therapy was delayed for 25 (7.8%) patients. Patients with normal body mass index (BMI) developed more hematomas (P = .042).

In African American (AA) patients, those with normal BMI had more complications (P = .003), hematomas (P < .001), and persistent pain (P = .011) than those with higher BMI. Additionally, AA patients with hyperlipidemia had more wound infections (P = .018).

Hispanic patients undergoing standard lumpectomy developed more infections than localized lumpectomy (P = .009). Standard lumpectomy had a higher wound infection risk than localized lumpectomy for patients 50 years or older, but this was not statistically significant (P = .054).

Table (cont.)

Table (cont.)

Conclusion

BCS is generally safe, but complications may delay adjuvant therapy. In our study, there were strong associations within race, but we did not find strong correlations between races. Nonetheless, future studies with larger sample sizes are warranted.

Articles in this issue

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content